Furthermore, many potential AML-associated antigens, such as CD33 and CD123, are also expressed on healthy hematopoietic stem and progenitor cells, increasing the risk of on-target, off-tumor toxicity (44). This evidence concerns the gene CD33 and acute myeloid leukemia.